cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...

As GLP-1 use expands, persistence remains a critical factor in realizing the therapies' full clinical potential

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

Prime Therapeutics researchers shared real-world insights at AMCP Nexus 2025 on GLP-1 utilization, treatment persistence and strategies to improve access to these high-demand therapies

Real-world, integrated data follows-up on previous insights, analytics.

PUBLICATIONS FDA Decisions Expected: August 2025 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References Press release:...

Prime Therapeutics discusses the challenges health plans face in expanding access to GLP-1 therapies while managing rising costs

Real-world research highlights patient persistence as a critical factor in achieving the long-term benefits of GLP-1 therapies

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...